Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025
Ligand Pharmaceuticals (NASDAQ:LGND) has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025. The company will host a conference call and webcast at 8:30 AM ET to discuss the quarterly performance and provide a business update.
Investors can access the call via phone at (800) 715-9871 (U.S. & Canada) or (646) 307-1963 (International) using Conference ID 3661098. A live webcast and replay will also be available through the company's website.
Ligand Pharmaceuticals (NASDAQ:LGND) ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per giovedì 7 agosto 2025. L'azienda terrà una conference call e una diretta web alle 8:30 AM ET per discutere delle performance trimestrali e fornire un aggiornamento sul business.
Gli investitori potranno partecipare alla chiamata telefonando al (800) 715-9871 (USA e Canada) o al (646) 307-1963 (internazionale) utilizzando il codice di conferenza 3661098. Sarà inoltre disponibile una diretta web e una registrazione sul sito web dell'azienda.
Ligand Pharmaceuticals (NASDAQ:LGND) ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el jueves 7 de agosto de 2025. La compañía realizará una llamada en conferencia y una transmisión en vivo a las 8:30 AM ET para discutir el desempeño trimestral y proporcionar una actualización del negocio.
Los inversionistas pueden acceder a la llamada por teléfono al (800) 715-9871 (EE.UU. y Canadá) o al (646) 307-1963 (internacional) usando el ID de conferencia 3661098. También estará disponible una transmisión en vivo y una repetición a través del sitio web de la compañía.
Ligand Pharmaceuticals (NASDAQ:LGND)는 2025년 2분기 재무 실적 발표를 2025년 8월 7일 목요일로 예정했습니다. 회사는 분기 실적을 논의하고 사업 업데이트를 제공하기 위해 동부시간 오전 8:30에 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다.
투자자들은 (800) 715-9871 (미국 및 캐나다) 또는 (646) 307-1963 (국제) 번호로 전화해 회의 ID 3661098을 사용하여 콜에 참여할 수 있습니다. 회사 웹사이트를 통해 생중계 및 다시보기 서비스도 제공됩니다.
Ligand Pharmaceuticals (NASDAQ:LGND) a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 pour le jeudi 7 août 2025. La société organisera une conférence téléphonique et une webdiffusion à 8h30 ET pour discuter des performances trimestrielles et fournir une mise à jour commerciale.
Les investisseurs peuvent accéder à l'appel par téléphone au (800) 715-9871 (États-Unis et Canada) ou au (646) 307-1963 (international) en utilisant l'ID de conférence 3661098. Une webdiffusion en direct et un replay seront également disponibles sur le site internet de la société.
Ligand Pharmaceuticals (NASDAQ:LGND) hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für Donnerstag, den 7. August 2025 geplant. Das Unternehmen wird um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Quartalsergebnisse zu besprechen und ein Geschäftsupdate zu geben.
Investoren können über die Telefonnummer (800) 715-9871 (USA & Kanada) oder (646) 307-1963 (international) mit der Konferenz-ID 3661098 an der Telefonkonferenz teilnehmen. Ein Live-Webcast sowie eine Aufzeichnung sind ebenfalls über die Website des Unternehmens verfügbar.
- None.
- None.
JUPITER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025. The company will hold a conference call beginning at 8:30 a.m. ET to discuss the results and provide a general business update.
Conference Call and Webcast Information
| Date: | Thursday, August 7, 2025 |
| Time: | 8:30 AM Eastern Time |
| Conference Call: | (800) 715-9871 (U.S. & Canada) (646) 307-1963 (International) Conference ID 3661098 |
| Webcast: | Live and replay webcasts of the call are available here. |
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X and LinkedIn.
We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.
Contacts
Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761
Media:
Kellie Walsh
media@ligand.com
(914) 315-6072
FAQ
When will Ligand (LGND) report Q2 2025 earnings?
What time is Ligand's Q2 2025 earnings call?
How can I listen to Ligand's Q2 2025 earnings call?
Will there be a replay of Ligand's Q2 2025 earnings call?
